Agency Response

Paul E. Marik, M.D. response to the American Board of Internal Medicine (“ABIM” or “Board”) letter of May 26, 2022  raising concerns that Dr. Marik is spreading medical misinformation regarding the prevention and treatment of COVID-19.

The response sent on behalf of Pierre Kory, MD to the American Board of Internal Medicine (ABIM) letter of May 26, 2022 raising concerns that Dr. Kory is spreading medical misinformation regarding the prevention and treatment of COVID-19.

The FLCCC Alliance commends the Publix Super Market's decision to not offer COVID-19 vaccinations to children five and younger.

ACTIV-6 severely limited the use of ivermectin, administering a dose below what is known to be effective on the variants at the time and received too late (6 days on average) after the onset of symptoms. Despite these obvious shortfalls, there was a statistically significant, albeit modest, impact on time to clinical recovery for patients using ivermectin to treat COVID-19. T

A reexamination of the data without the earlier research continues to prove that ivermectin is effective in preventing and treating COVID-19

Transcript of Dr. Kory's video message on the U.S. Deal to Give $1.2 Billion Taxpayer Dollars to Merck Instead of distributing safe, effective, inexpensive ivermectin

Awareness of ivermectin’s efficacy and its adoption by physicians worldwide to successfully treat COVID-19 have grown exponentially over the past several months.

A global panel providing legal, ethical, clinical and political perspectives on the failure of public health organizations to recommend the worldwide use of ivermectin – a scientifically proven medicine to prevent and treat COVlD-19.

The World Health Organization and National Institutes of Health now have all the data they need to recommend ivermectin to prevent and treat COVID-19. And those who want to end this pandemic now, for all countries rich and poor, should welcome that move.

Despite the rapidly increasing and diverse amounts of medical evidence supporting ivermectin as a life-saving therapy in COVID, multiple national and international health agencies – including but not limited to the World Health Organization, the European Medicines Agency, and the regulatory health agencies of all of North America and Europe – have continued to issue negative recommendations against use of ivermectin in COVID-19.

The Front Line COVID-19 Critical Care Alliance (FLCCC), a group of highly published, world-renowned critical care physicians and scholars, today praised the recent updated guidance from the All India Institute of Medical Science (AIIMS) to include ivermectin in its guidelines for the treatment of COVID-19.

WHO ignores significant data, including several large clinical trials, while claiming insufficient evidence to recommend the use of ivermectin to prevent and treat COVID-19

The FLCCC Alliance is troubled by the recently updated consumer guidance on Ivermectin from the FDA. The guidance from the FDA is misleading and has the potential to raise unwarranted concern over an important drug in the prevention and treatment of COVID-19.

On January 6, 2021, Dr. Paul Marik and Dr. Pierre Kory – founding members of the Front Line Covid-19 Critical Care Alliance (FLCCC) – along with Dr. Andrew Hill, researcher and consultant to the World Health Organization (WHO), presented their data on ivermectin before the National Institutes of Health (NIH) Treatment Guidelines Panel.

FLCCC Alliance Invited to the National Institutes of Health (NIH) COVID-19 Treatment Guidelines Panel to Present Latest Data on Ivermectin FLCCC Urges Expedited Review of Current Data and an Updated NIH Guidance